The potential anti-tumor effect of recombinant yeast-brachyury vaccination was evaluated in C57BL/6 mice that were intravenously injected with MC38-pBrachyury cells on day 0 and subsequently vaccinated weekly from day 4 with 1 YU per site at four sites with recombinant yeast-brachyury or the control yeast vaccine, until sacrifice on day 36. Here, TBX1 is linked to neoplasm.